USP25 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL11479715	0.40	11/20
SCHEMBL11102626	0.52	9/20
SCHEMBL4898236	0.60	8/20
SCHEMBL13339652	0.44	8/20
SCHEMBL8801032	0.43	8/20
SCHEMBL4898944	0.59	7/20
SCHEMBL11102077	0.46	7/20
SCHEMBL4297581	0.34	7/20
SCHEMBL1968718	0.31	7/20
SCHEMBL12562427	0.53	6/20
SCHEMBL4131579	0.46	6/20
SCHEMBL3492612	0.44	6/20
SCHEMBL9542517	0.40	6/20
SCHEMBL4898520	0.72	5/20
SCHEMBL4894197	0.67	5/20
SCHEMBL4887038	0.66	5/20
SCHEMBL4890911	0.66	5/20
SCHEMBL4897726	0.56	5/20
SCHEMBL4897091	0.51	5/20
SCHEMBL11486062	0.38	5/20

Clinical trials — most relevant to USP25 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer	PHASE3	COMPLETED
Multi-site Adaptive Trials for COVID-19	PHASE3	COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection	PHASE2	WITHDRAWN
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	PHASE2	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	nan	COMPLETED
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Long Term Prediction of MASH-related HCC Risk by Proteomics	nan	NOT_YET_RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a USP25 binder may also engage these)

Protein	Name	Similarity
P57080	—	1.000	P57080 →
USP28	Ubiquitin carboxyl-terminal hydrolase 28	0.990	landscape →
Q5I043	—	0.984	Q5I043 →
D3ZJ96	—	0.983	D3ZJ96 →
Q8CFQ3	—	0.981	Q8CFQ3 →
Q7SH49	—	0.981	Q7SH49 →
Q5AW75	—	0.981	Q5AW75 →
Q7YZT6	—	0.981	Q7YZT6 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.980	landscape →
A1CS06	—	0.980	A1CS06 →
P24583	—	0.979	P24583 →
Q6ZPS6	—	0.979	Q6ZPS6 →
Q12242	—	0.979	Q12242 →
Q5ZID5	—	0.979	Q5ZID5 →
O42947	—	0.979	O42947 →
Q80U87	—	0.979	Q80U87 →
Q0CLX3	—	0.979	Q0CLX3 →
A2QHV0	—	0.978	A2QHV0 →
Q12451	—	0.978	Q12451 →
A8WRG3	—	0.978	A8WRG3 →
Q6BIP2	—	0.978	Q6BIP2 →
Q6DGK9	—	0.978	Q6DGK9 →
Q86UV5	—	0.978	Q86UV5 →
A1CW53	—	0.978	A1CW53 →
Q9P3U0	—	0.978	Q9P3U0 →
Q9M086	—	0.978	Q9M086 →
Q9FFQ0	—	0.978	Q9FFQ0 →
Q5F499	—	0.978	Q5F499 →
O60306	—	0.978	O60306 →
Q24574	—	0.977	Q24574 →